In the phase III CheckMate-77T trial evaluating the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo in patients with resectable stage 2A to 3B non-small cell lung cancer, the perioperative regimen showed a statistically significant and clinically meaningful improvement in the primary efficacy endpoint of event-free survival as assessed by Blinded Independent Central Review compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo.
Johnson & Johnson announced positive topline results for overall survival from the phase III MARIPOSA study, evaluating Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions (ex19del) or L858R substitution mutations.
